Flexion Reports First Quarter 2017 Financial Results And Recent Business Highlights

BURLINGTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results for the quarter ended March 31, 2017.

“The first few months of 2017 marked another period of impressive growth for Flexion,” commented Michael Clayman, M.D., President and Chief Executive Officer. “We continued to attract top talent, made great progress building our commercial infrastructure, strengthened the IP estate for Zilretta and significantly advanced our launch plans. Furthermore, following our recent convertible debt offering, we believe we now have the capital to take us well into 2019, more than one year after the anticipated launch of Zilretta. We are excited about Flexion’s future and the potential to make a meaningful difference for the millions of patients confronting OA.”

Back to news